Emerging antibiotic resistance in urinary tract pathogens (Q35171761)

6 August 2017

1 reference

title

Emerging antibiotic resistance in urinary tract pathogens (English)

1 reference

6 August 2017

main subject

antibiotic resistance

1 reference

Kalpana Gupta

1

1 reference

6 August 2017

publication date

1 June 2003

1 reference

Infectious Disease Clinics of North America

6 August 2017

published in

1 reference

6 August 2017

volume

17

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

243-259

1 reference

Management of acute uncomplicated urinary tract infection in adults

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA).

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

A randomized trial of short-course ciprofloxacin, ofloxacin, or trimethoprim/sulfamethoxazole for the treatment of acute urinary tract infection in women. Ciprofloxacin Urinary Tract Infection Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Increasing prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in women

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Prevalence and predictors of trimethoprim-sulfamethoxazole resistance among uropathogenic Escherichia coli isolates in Michigan

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

The prevalence of antimicrobial resistance among uropathogens causing acute uncomplicated cystitis in young women

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in women: a nationwide analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

A Canadian national surveillance study of urinary tract isolates from outpatients: comparison of the activities of trimethoprim-sulfamethoxazole, ampicillin, mecillinam, nitrofurantoin, and ciprofloxacin. The Canadian Urinary Isolate Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Prevalence of antimicrobial resistance among urinary tract pathogens isolated from female outpatients across the US in 1999.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Ofloxacin versus trimethoprim-sulfamethoxazole for treatment of acute cystitis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Diagnosis and treatment of uncomplicated urinary tract infection

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

A multicenter comparative trial of three-day norfloxacin vs ten-day sulfamethoxazole and trimethoprim for the treatment of uncomplicated urinary tract infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

The ECO*SENS Project: a prospective, multinational, multicentre epidemiological survey of the prevalence and antimicrobial susceptibility of urinary tract pathogens-interim report

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Pathogen occurrence and antimicrobial resistance trends among urinary tract infection isolates in the Asia-Western Pacific Region: report from the SENTRY Antimicrobial Surveillance Program, 1998-1999.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Empiric use of trimethoprim-sulfamethoxazole (TMP-SMX) in the treatment of women with uncomplicated urinary tract infections, in a geographical area with a high prevalence of TMP-SMX-resistant uropathogens.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Antimicrobial susceptibility of community-acquired uropathogens in northern Israel.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY antimicrobial surveillance program (1998).

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Multicenter in vitro comparative study of fluoroquinolones against 25,129 gram-positive and gram-negative clinical isolates.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Ten-year survey of quinolone resistance in Escherichia coli causing urinary tract infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Extended spectrum beta-lactamase production and fluorquinolone resistance in pathogens associated with community acquired urinary tract infection

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Antibiotic sensitivity of bacteria associated with community-acquired urinary tract infection in Britain

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

In vitro susceptibility of vancomycin-resistant enterococci (VRE) to fosfomycin

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

In-vitro susceptibility of quinolone-resistant clinical isolates of Escherichia coli to fosfomycin trometamol

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Correlation of oxacillin MIC with mecA gene carriage in coagulase-negative staphylococci.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Oxacillin susceptibility testing of Staphylococcus saprophyticus using disk diffusion, agar dilution, broth microdilution, and the Vitek GPS-105 card

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

A disseminated multidrug-resistant clonal group of uropathogenic Escherichia coli in pyelonephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Therapy for women hospitalized with acute pyelonephritis: a randomized trial of ampicillin versus trimethoprim-sulfamethoxazole for 14 days.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Comparison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis pyelonephritis in women: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Resistance patterns among nosocomial pathogens: trends over the past few years

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: a report from the SENTRY Antimicrobial Surveillance Program (North America).

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

A European perspective on nosocomial urinary tract infections I. Report on the microbiology workload, etiology and antimicrobial susceptibility (ESGNI-003 study). European Study Group on Nosocomial Infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Epidemiology of bacteriuria caused by vancomycin-resistant enterococci--a retrospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Treatment options for vancomycin-resistant enterococcal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Bacteremia caused by Escherichia coli producing extended-spectrum beta-lactamase: a case-control study of risk factors and outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Multidrug-resistant urinary tract isolates of Escherichia coli: prevalence and patient demographics in the United States in 2000.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Ciprofloxacin-resistant Escherichia coli emerging in a rehabilitation medical center

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Current microbiological and clinical aspects of urinary tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Antibiotic use and Escherichia coli resistance trends for quinolones and cotrimoxazole in Sweden

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Urinary tract infections and a multidrug-resistant Escherichia coli clonal group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Emergence of resistant fecal Escherichia coli in travelers not taking prophylactic antimicrobial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Risk factors for fecal colonization with trimethoprim-resistant and multiresistant Escherichia coli among children in day-care centers in Houston, Texas

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Intrafamilial spreading of Escherichia coli resistant to trimethoprim.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

An epidemic of urinary tract infections?

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Widespread distribution of urinary tract infections caused by a multidrug-resistant Escherichia coli clonal group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Transferable high-level trimethoprim resistance among isolates of Escherichia coli from urinary tract infections in Ontario, Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

High-dosage co-amoxiclav in a single dose versus 7 days of co-trimoxazole as treatment of uncomplicated lower urinary tract infection in women

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

National patterns in the treatment of urinary tract infections in women by ambulatory care physicians

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Emergence of ciprofloxacin resistance in Escherichia coli isolates after widespread use of fluoroquinolones

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Correlation between increased consumption of fluoroquinolones in outpatients and resistance of Escherichia coli from urinary tract infections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Increasing resistance to fluoroquinolones in escherichia coli from urinary tract infections in the netherlands

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Efficacy of norfloxacin in urinary tract infection biological effects on vaginal and fecal flora.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

Prevalence and risk factors for multidrug resistant uropathogens in ED patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5520%2803%2900006-0

7 January 2021

10.1016/S0891-5520(03)00006-0

Identifiers

DOI

1 reference

6 August 2017

1 reference